Oramed
 | |
| Type | Public |
|---|---|
| Nasdaq: ORMP Russell Microcap Index component TASE: ORMP | |
| ISIN | US68403P2039  |
| Industry | Biotech |
| Founded | 2006 |
| Headquarters | |
Key people | Nadav Kidron (CEO) |
| Website | oramed |
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
[edit]Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.[1][2]
Product pipeline
[edit]Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.[3][4][5]
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.[6][7]
In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge.[8] The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset. [4]
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.[9]
On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.[4][10]
Subsidiaries
[edit]OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
See also
[edit]References
[edit]- ↑ Weinreb, Gali (15 January 2013). "Insulin pill co Oramed jumps on Nasdaq listing plans". Globes. Retrieved 16 February 2013.
- ↑ Blackburn, Nicky (24 June 2007). "Israeli patent moves closer to achieving oral insulin treatment". Israel21c. Retrieved 16 February 2013.
- ↑ Leichman, Abigail Klein (12 February 2013). "Groundbreaking insulin pill nearing market". ISRAEL21c. Retrieved 8 May 2025.
- 1 2 3 "Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop". clinicaltrialsarena.com. 21 February 2024. Retrieved 3 May 2025.
- ↑ "Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2" (PDF). mayafiles.tase.co.il.
- ↑ "Israel developing injectable and oral vaccines as COVID cases soar". MobiHealthNews. 17 August 2021. Retrieved 8 May 2025.
- ↑ "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post. 22 July 2021. ISSN 0792-822X. Retrieved 8 May 2025.
- ↑ "Oramed plunges after reporting trial failure". Globes. Retrieved 4 May 2023.
- ↑ Serafino, Phil; Odenheimer, Alisa (2 May 2023). "Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company". Bloomberg. Retrieved 4 May 2023.
- ↑ Pharmaceuticals, Oramed (13 December 2018). "Oral Insulin Moves Towards Becoming Reality in U.S., China". Global Trade Magazine. Retrieved 8 May 2025.
| Healthcare | |
|---|---|
| Communication & Networks | |
| Software | |
| Electronics | |
| Security & defense | |
| Consumer goods | |
| Financial services | |
| Conglomerates | |
